Twist Bioscience secures $140M plus a slew of new DNA partnerships

3D medical background with DNA strand
The collaborations are geared toward narrowing the focus of whole genome sequencing efforts to specific regions of interest. (kirstypargeter/iStock/Getty Images Plus)

Synthetic DNA weaver Twist Bioscience announced a handful of new collaborations this week, amidst a $140 million raise from an underwritten public offering.

The team-ups are working on delivering a new solution focused on data and genomic analysis, with the help of Sophia Genetics, as well as the development of target enrichment tools and library preparation kits through collaborations with GenapSys and Miroculus.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Overall, the collaborations are geared toward narrowing the focus of whole genome sequencing efforts to specific regions of interest, to provide researchers with deeper information on the roles that individual genes play in health and disease.

“Genomics research is enabling a shift from broad-based 'one-size-fits-all' approach to a personalized experience,” said Twist co-founder and CEO Emily Leproust.

Twist will work with Sophia Genetics to help bring the latter’s artificial intelligence-powered data platform to its customers to help interpret DNA sequencing results in somatic and germline testing.

“The combined solution will ultimately help experts precisely detect and characterize genomic mutations and use that information to improve outcomes,” said Sophia Genetics co-founder and CEO Jurgi Camblong.

Meanwhile, Twist’s additional partnerships will see the company develop a broad range of target enrichment and library preparation tools compatible with GenapSys’ sequencers and Miroculus’ next-generation sequencing workflow automation platforms. GenapSys plans to integrate Twist’s products beginning in the second quarter of this year.

All this and more will be fueled by the approximate $140 million brought in by Twist, by selling over 5.3 million shares of common stock at $28 apiece. The company has slated the net proceeds for its R&D programs—which include investments in biologic drug discovery and DNA data storage research—as well as its global expansion.

Suggested Articles

Bayer strengthened its ties with Scottish AI developer Blackford Analysis to build a one-stop shop for applications in medical imaging.

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Boston Scientific has moved to hive off the specialty pharmaceuticals division it picked up through last year’s $4.2 billion acquisition of BTG.